Literature DB >> 27274192

Segmentation and removal of fibrovascular membranes with high-speed 23 G transconjunctival sutureless vitrectomy, in severe proliferative diabetic retinopathy.

Erkan Celik1, Ozkan Sever2, Fatih Horozoglu2, Ates Yanyalı3.   

Abstract

AIM: To evaluate the effectiveness and safety of high-speed (5,000 cuts per minute) 23 G transconjunctival sutureless vitrectomy (TSV) in severe diabetic fibrovascular proliferation (DFVP). PATIENTS AND METHODS: In this retrospective consecutive case series, patients who underwent 23 G TSV for severe DFVP between October 2011 and March 2014 at our institution were evaluated. 23 G TSV was performed with a high-speed (5,000 cuts per minute) cutter without a chandelier light.
RESULTS: The mean follow-up period was 8 months (range: 4-23 months). Of the 27 eyes of 27 patients, 14 eyes (52%) underwent concomitant phacoemulsification with posterior chamber intraocular lens implantation, nine eyes (33%) were pseudophakic, and four eyes were phakic (15%). DFVP was removed with ease in all, and visual acuity was improved in 18 (67%) eyes. Iatrogenic retinal tear was observed in four eyes (15%) and treated successfully during surgery. Suture placement to a single sclerotomy was performed in eight eyes (30%). Postoperative intraocular hemorrhage was observed in five eyes (18%). Cataract formation was observed in two of the four phakic eyes. Three (11%) patients had postoperative intraocular pressure rise. Postoperative hypotony (≤6 mmHg) and endophthalmitis were not observed in any eye.
CONCLUSION: The segmentation and removal of fibrovascular membranes with high-speed 23 G TSV seems to be a safe and easy method in severe diabetic eye disease.

Entities:  

Keywords:  diabetic fibrovascular proliferation; high speed; transconjunctival sutureless vitrectomy

Year:  2016        PMID: 27274192      PMCID: PMC4876088          DOI: 10.2147/OPTH.S95145

Source DB:  PubMed          Journal:  Clin Ophthalmol        ISSN: 1177-5467


Introduction

Traditionally, 20 G vitrectomies are the most practiced vitrectomy for a variety of vitreoretinal diseases, including diabetic fibrovascular proliferation (DFVP).1 The last 30 years have been very beneficial for the improvement of vitrectomy systems. When compared to the old 20 G vitrectomy systems, which use 0.89 mm sclerotomies, the new techniques use smaller sclerotomies and are less complicated.2 Fujii et al first introduced 25 G transconjunctival sutureless vitrectomy (TSV) in 2002 following a self-sealing sclerotomy that was described by Chen.3,4 However, usage of 25 G TSV presented some problems, including the significant flexibility of the instruments, resulting in reduced manipulation, inadequate illumination, and reduced lumen of the microcannula for fluid flow.5–7 In 2005, Eckardt8 presented a 23 G TSV and solved the flexibility problems, allowing greater ocular rotation and ability to apply it to more complicated vitreoretinal diseases, such as DFVP. Several studies reported the safety and effectiveness of the 23 G pars plana vitrectomy (PPV).9–12 Recently, new vitrectomy systems with ultrahigh-speed cut rates (5,000 cuts per minute [cpm]) and duty cycle controls have become available.13 The benefits of these new systems are that a greater cut rate reduces vitreous turbulence by allowing only small pieces of vitreous to enter the port, resulting in little retinal traction. In addition, a greater cut rate and a maximum port opening increase the efficacy of the system.14–17 The aim of this study was to evaluate the effectiveness and safety of segmentation and removal of membranes with ultrahigh-speed (5,000 cpm) 23 G TSV in eyes with severe DFVP. In conclusion, fibrovascular proliferation is a challenging complication of severe diabetic eye disease. Segmentation and removal of membranes with ultrahigh-speed 23 G vitrectomy with 5,000 cpm seems to be effective in the treatment of this condition with an acceptable intra- and postoperative complication rate.

Patients and methods

Patients

In this retrospective noncomparative study, we inspected 27 eyes of 27 consecutive patients who underwent high-speed (5,000 cpm) 23 G TSV with segmentation technique for severe DFVP between October 2011 and March 2013 at the Department of Ophthalmology in Namik Kemal University, School of Medicine. The research was conducted in accordance with the Declaration of Helsinki, and all patients signed a written informed consent after receiving an explanation of possible consequences of the operations.

Inclusion/exclusion criteria

Inclusion criterion was patients with diabetic fibrovascular membranes that threaten the macula. Threat to the macula was considered as fibrovascular membranes close to the avascular foveal zone inside and over the vascular arcade. Assessment of macula-threatening lesion was made by clinical examination and noted routinely by the same experienced surgeon (FH) before the operations. The exclusion criteria included history of prior vitrectomy, glaucoma filtration surgery, intractable glaucoma, and vitreous hemorrhage (VH) without fibrovascular proliferation. All patients received anterior segment examination, intraocular pressure measurement with applanation tonometry, a best-corrected Snellen visual acuity measurement, and biomicroscopic evaluation with fundus noncontact lenses. All eyes without visualization of fundus underwent B-scan ultrasonography. All Snellen visual acuities were converted into logarithm of the minimum angle of resolution units. Intraocular pressure levels ≥21 mmHg were accepted as elevated intraocular pressure.

Methods

Surgical technique

All the operations were performed by the same surgeon (FH). The two-step 23 G vitrectomy system (Stellaris PC; Bausch and Lomb, Rochester, NY, USA) was used in all cases. When the patient had a significant cataract, combined phacoemulsification and intraocular lens implantation were performed through a 2.8 mm clear corneal incision before the scleral incision for vitrectomy was made. Insertion trocars were implanted in the superotemporal, inferotemporal, and superonasal quadrants, and microcannulas were implanted through them 3–3.5 mm posterior to the limbus. A 23 G microvitreoretinal blade was inserted tangentially at an angle of ~30°, parallel to the limbus. Microcannulas were inserted transconjunctivally with the help of the insertion trocars in the inferotemporal, superotemporal, and superonasal quadrants, 3.5 mm posterior to the limbus. 23 G microvitreoretinal blade was used at an angle of 30°, tangent to the limbus. The inferotemporal quadrant was used for infusion cannula, and other entry sites were temporarily closed by plugs. The high-speed vitrectomy probe (Bausch and Lomb) of the surgical system (Stellaris PC; Bausch and Lomb) with a cutting rate of 5,000 cpm and vacuum levels of 150–300 mmHg was used during PPV. Bottle height for operations was 40 cm. After core vitrectomy, the vacuum level was settled a 200 mmHg, and peripheral vitreous and tractions between the anterior and posterior vitreous were removed. Posterior vitreous detachment was resolved using a silicone-tipped cannula by passive aspiration and then continued 360° peripherally. Endoilluminator probe was used as a second hand, and a cleavage was created with either a membrane pick or a 25 G needle through the membrane. Shaving of the membranes at the retina plane with the high-speed vitrectomy was performed under a wide-angle viewing system using a vacuum level of 100–150 mmHg and a cutting rate of 5,000 cpm. At the end of each surgery, air–fluid exchange was always carried out, and endolaser treatment and endotamponades were performed when required. For standard cases, we used air as endotamponade, but for complicated cases (intraoperative retinal tear and extensive fibrovascular tissue dissection), perfluoropropane (C3F8) gas or silicone oil was used. In group 1, air was selected as a tamponade, whereas in group 2 and eyes with iatrogenic tear, C3F8 gas was selected as a tamponade, and if the patient had a contraindication for gas (flying, climbing, etc), silicone oil was selected as a tamponade. At the end of the operation, microcannulas were gently removed from the eye. The conjunctival tissue over the sclerotomy was displaced to avoid the formation of a fistula. A little bit of massage with a muscle hook was used to ensure there was no leakage. The sclerotomy site was sutured with 7/0 Vicryl, if any sign of leakage was detected, such as a bleb formation or hypotony, after the application of 20 seconds compression three times. Corticosteroid (dexamethasone, 4 mg) and antibiotic (cefazolin, 50 mg) were injected into the subconjunctival space. Topical antibiotics and steroids were prescribed postoperatively for 1 month. Main results were visual and anatomical outcomes, and then as secondary results, postoperative and intraoperative results were recorded. Time points for postoperative examinations were first day, first week, first month, third month, and 3 months. However, not all the patients were present at each call. All patients were present only at postoperative first day visit.

Statistical analysis

Statistical analysis was performed using the PASW Statistics (SPSS for Windows, version 18.0, SPSS, Chicago, IL, USA). P-values of <0.05 were considered as statistically significant. All the patients were informed about possible risks of the treatment, and an informed consent was prepared according to the Declaration of Helsinki. Namık Kemal University School of Medicine Local Ethical Committee waived the requirement to obtain approval from institutional review board for retrospective studies.

Results

The clinical characteristics of the patients are summarized in Table 1. The mean age at surgery was 61.9 years (range: 46–80 years). Male to female ratio was 15:12 (55%:45%). The mean follow-up period was 8.3 months (range: 4–23 months). DFVP was removed with ease from all eyes. Fourteen eyes (52%) underwent concomitant phacoemulsification with posterior chamber intraocular lens implantation, nine eyes (33%) were pseudophakic, and four eyes were phakic (15%). Eleven eyes (41%) were given intravitreal bevacizumab (IVB) (Altuzan®, Roche®, Basel, Switzerland) within 1 week prior to surgery. Nineteen eyes (70%) received air, six eyes (22%) received C3F8 gas, and two eyes (8%) received silicone oil as endotamponade. Suture placement for a single sclerotomy was performed in eight (30%) eyes at the end of the surgery. Suture placement was not required for any eyes during the postoperative follow-up period.
Table 1

Preoperative, intraoperative, and postoperative clinical characteristics of eyes that received 23 G transconjunctival sutureless vitrectomy with high-speed (5,000 cpm) cutter

NoAgeSexFollow-up time (months)Preoperative VAPostoperative VAPhacicCombined Phaco-PPVPreoperative IVBSutureTamponadeComplications
180M6HM0.7NNNNAirN
271F9CF0.05YYNYAirGlaucoma
359F9HMCFYNNNC3F8Cataract
458F110.50.6NNNYSilicone oilN
551M40.30.2NNYNAirGlaucoma
646F6.5HM0.1YYNNC3F8IRT
763M14.5CF0.2NNNYC3F8N
866M5CFCFNNNNAirN
957F60.10.1YYYNAirN
1060F8CF0.3YYNNAirVH
1157M70.10.4YYNNAirN
1249M9.50.10.2YYYNAirN
1378M6CF0.05YNYNAirCataract
1478M5CF0.05YYYNAirN
1554F9HMHMYYNYAirVH
1651F19CF0.05YYYNAirVH
1763M110.10.1YNYYC3F8IRT
1864M120.050.05YYYYSilicone oilGlaucoma
1962F8HM0.2NNNNAirVH
2061M60.20.2YYYYC3F8N
2165M11CF0.1YYNNAirN
2260M5CF0.4YNYNC3F8N
2363F70.10.1YYNNAirVH
2463F13HM0.05NNYNAirN
2566M6HM0.3YYNNAirIRT
2657F60.20.2NNNYAirN
2769M5CF0.1NNNNAirIRT

Abbreviations: C3F8, perfluoropropane; CF, counting fingers; F, female; HM, hand motions; IRT, iatrogenic retinal tear; IVB, intravitreal bevacizumab; M, male; N, no; Phaco-PPV, phacoemulsification-pars plana vitrectomy combined surgery; VA, visual acuity (Snellen); VH, vitreous hemorrhage; Y, yes.

Visual acuity was between hand motions and 0.5 preoperatively (median counting fingers) and hand motions and 0.7 (median 0.1) postoperatively. Visual acuity improvement was achieved in 18 eyes (67%). Visual acuity remained the same in eight eyes (30%) and decreased in one eye (3%) due to postoperative cystoid macular edema. Mean postoperative intraocular pressure was 14.8±6.7 mmHg preoperatively and 15.0±6.6 mmHg postoperatively (P>0.05). Any rise in IOP was treated with medication. Postoperative 6-month visual acuity and IOP were 0.90±0.55 logarithm of the minimum angle of resolution and 11.49±3.1 mmHg, respectively. Combined surgery had 0.12 Snellen visual acuity gain at postoperative month 6, and PPV alone had 0.18 Snellen visual acuity gain at postoperative month 6. Postoperative complications were five intravitreal hemorrhages, and four of the hemorrhages did not use bevacizumab. Postoperative intraocular hemorrhage was observed in five eyes (18%). In four of these eyes, hemorrhage resolved spontaneously, whereas secondary wash-out vitrectomy was performed in the other eye. Cataract formation (two of the four phakic eyes), iatrogenic retinal tear (15%), and rise in IOP (11%) were the postoperative complications. Postoperative hypotony (≤6 mmHg) and endophthalmitis were not observed in any eye.

Discussion

Neovascularization with or without fibrous proliferation is the hallmark of proliferative diabetic retinopathy (PDR).18 Contraction of the proliferative fibrovascular membranes causes hemorrhages and retinal detachment, which may lead to blindness if not properly treated.19,20 Surgical treatment for fibrovascular membranes may relieve tractions and improve vision. The most effective and proven treatment for the complications of PDR is PPV, with good success.21–25 There are different dissection techniques for proliferative fibrovascular membrane surgery some of the surgeons prefer to use the en bloc excision of membranes, and some of them use the segmentation or delamination techniques. High-speed vitrectomy has got several advantages, but the mostly accepted benefit is less traction and less retinal detachment. We preferred to use segmentation and removal of membranes with high-speed cutter in all cases. All surgical innovations for vitrectomy surgeries aimed to find the less invasive and faster method. Of late, the advent of 23 G and 25 G instruments has begun to change the importance of conventional 20 G vitrectomy with its benefits, such as faster surgery and quicker healing time.4,5,26,27 TSV has several advantages over traditional 20 G vitrectomy.6,8,9,27 Smaller incisions result in faster wound healing, thanks to self-closing sclerotomy (without peritomy). All these result in less scarring on the conjunctiva, and less patient disturbance, postoperative inflammation, and astigmatism.28–31 Although TSV was recommended for macular pathologic features or simple VH because of the limited designs and fragility of small-gauge instrumentation in the initial stage, recent invention of rigid instrumentation and bright light sources has expanded the indications for TSV to comprise more complex vitreoretinal disorders, such as PDR.6,9,10,32,33 TSV should be more suitable than traditional 20 G PPV for treating PDR because the conjunctiva-preserving nature of TSV allows repeated vitrectomy or filtering surgery that may be needed in patients with diabetes complicated with neovascular glaucoma even after vitrectomy. Less postoperative inflammation associated with TSV may facilitate early visual recovery in PDR as well as in macular diseases. However, it still remains a concern whether complex intraocular manipulations, such as fibrovascular membrane dissection and hemostasis in diabetic vitrectomy, can be managed steadily using small-gauge instrumentation.34 Besides, one of the main obstacles of small-gauge vitrectomy is longer vitrectomy time (because of longer bulk vitreous removal) compared to 20 G vitrectomy systems,4,5 which equalizes the saved time for wound opening and closing.14,35–37 Along with this, dense hemorrhages and epiretinal membranes and tight vitreous strands may be more difficult to remove.13 Recently, to overcome these problems, new vitrectomy systems with high-speed cut rates (5,000 cpm) and duty cycle controls have become available. As for the benefits of this system, 5,000 cpm cut rate results in a less vitreous turbulence with small pieces of vitreous aspiration, the chance to work with a maximum port opening while also using higher cutting rate and minimal traction on retinal surface.14–17 Vitreous is a kind of gelatinous fluid formed of 2% protein and 98% liquid and bigger particles may occlude port but the advantage of higher cut rate leads to aspiration of smaller pieces without causing serious port occlusion.16,38 Moreover, for less tractions on retina, “port-based flow-limiting” vitrectomy leads to a decreased flow (volume per open–close cycle) and greater fluidic stability.13 During our surgeries, we observed that high-speed vitrectomy (5,000 cpm) provides maximum fluidic stability, thanks to port-based flow limitation. Moreover, high-speed cutter diminishes the need for bimanual technique with chandelier light. Few studies have evaluated the safety and efficacy of the TSV for severe complicated vitreoretinal diseases.33,39–41 Oliveira and Reis40 reported the surgical results of 20 cases treated with the 23 G TSV and silicone oil tamponade. Altan et al41 reported the surgical outcome of 25 G TSV for the diabetic tractional detachment, which included six cases of bimanual technique. Park et al42 reported the short outcome of bimanual 23 G TSV for patients with complicated vitreoretinopathies, including PDR. The anatomical success rate ranged from 72.2% to 100%, and the rate of visual impairment ranged from 61.5% to 85% in these previous studies. In this study, with a limited case series, DFVP was removed with ease in all eyes by 23 G high-speed cutter, and visual acuity improvement was achieved in 67% of eyes. Recently, Rizzo et al13 reported a study between a standard new ultrahigh-speed 25 G system (Alcon Constellation, Fort Worth, TX, USA; 5,000 cpm) and 25 G TSV (Alcon Accurus, 1,500 cpm) in the treatment of different vitreoretinal diseases. They showed that iatrogenic retinal breaks and duration of vitrectomy time were significantly shorter in the new high-speed 25 G group. However, a direct comparison between each of the reports is not possible because these studies were limited by small descriptive case series with short-term follow-up, limited information about the severity of the vitreoretinal disease, different patient populations, and the use of different surgical methods. Visual outcomes and anatomical results of PDR are mostly unpredictable.43 Anatomical outcomes are mostly related to vitreoretinal adhesion, degree of fibrous tissue, and high rates of iatrogenic tears, which complicate the surgery.44–46 Some patients needed silicone oil, while some others had preceding ischemic maculopathy and macular dysfunction as a result of long duration of macular traction.25,45,47 Although vitreoretinal techniques have evolved, the incidence of iatrogenic retinal breaks is still significantly high. Simple VHs to complex DFVP ratio was 12%:78% for iatrogenic tears.48,49 Issa et al50 compared the retinal breaks observed during 23 G TSV vs conventional 20 G PPV for PDR and reported that there was a significant reduction in the incidence of peripheral retinal breaks in the 23 G group (5%) using the Alcon Accurus and Constellation cutters with higher cut rates (2,500/5,000 cpm) compared to 20 G group (16%). According to a study reported by Park et al,2 retinal breaks were observed in 15.2% of 66 eyes operated on using 20 G surgery compared to 8.6% of 35 eyes operated on using 23 G TSV for PDR. In a study evaluating the effectiveness of high-speed (5,000 cpm) 25 G PPV in the treatment of various vitreoretinal diseases, no retinal break was reported in six eyes operated for PDR.13 In this study, we observed iatrogenic retinal break in 15% of eyes. We believe that uncut vitreous fibers can be prevented with higher cut rates, and as a result of this, aspirated tissue volume is decreased, with lesser fluctuation and easier vitreous cleaning (shaving) close to the mobile peripheral retina. All these result in less retinal traction and breaks. Measuring the traction force on retina during vitrectomy has always been an issue so far. Teixeira et al51,52 used porcine eyes to show this challenge and found that retinal traction is decreased with higher cut rates and increased with proximity to the retina, and reported that for each 500 cpm increase, a decrease of 2.51 dynes of traction force was observed on the retina. Combining preoperative IVB with surgery is a good alternative to treat PDR. Mainly, two surgical rules determine the efficacy of therapy: eliminating intraoperative complications by pharmacologic involution of retinal neovascularization and simplifying the segmentation and delamination of membranes with fewer instrument exchanges, and minimizing intraoperative bleeding.34 Although the effect of bevacizumab is difficult to evaluate objectively, recent studies of off-label IVB injections have reported the efficacy and safety of bevacizumab for intraocular bleeding and postoperative complications in vitrectomy.53–56 In this study, eleven eyes (41%) were given IVB within a week prior to surgery. Intraoperative bleeding during the removal of fibrovascular membranes was observed in almost all the cases, but most bleeding was minor and preoperative IVB. VH is a common indication for PPV in PDR and is a relatively common postoperative complication.57 Prior studies have found different rates ranging from 10.2% to 63%. Park et al2 reported VH rate of 11.4% for the eyes with PDR treated with 23 G TSV. In this study, VH developed in five of the 27 eyes (18%). One of these patients had received IVB. Several studies have found decreased VH rates with preoperative or intraoperative IVB in PPV for PDR.58,59 In addition, IVB has been shown to hasten the clearance of postoperative VH.60 On the other side, some studies claim that the use of preoperative IVB does not help to reduce postoperative VH, but intraoperative IVB application reduces VH risk significantly.61 Besides, there have also been reports that preoperative IVB may exacerbate tractional retinal detachment.62 Cataract formation and vitreoretinal diseases usually occur together, especially in the elderly population, and the intraoperative visualization of the posterior segment during vitrectomy can be affected by lens opacity. In addition, if the cataract is not significant at the time of vitrectomy, vitreoretinal surgery and usage of an intraocular tamponade can accelerate the process of cataract formation.63 Combined vitreoretinal and cataract surgery has numerous advantages, including less risk of anesthesia, better visualization of intraoperative retina, performing sufficient peripheral vitrectomy, improving early visual rehabilitation, and the necessity of only one operation, which may reduce patient discomfort and decrease the costs.64 However, simultaneous cataract and vitreoretinal surgery has potential disadvantages, including difficulty in visualizing the capsulorhexis due to an absent or reduced red reflex in eyes with PDR and a number of other potential complications.63–65 Postoperative hypotony, with or without an accompanying wound leak, is a well-known complication of sutureless vitrectomy. Studies showed that postoperative hypotony (defined as <6) is between 2% and 10%.9–12,66 In our cases, we found no hypotony even with total vitrectomy, including vitreous base, known as one of the major risk factors for sclerotomy leakage. Factors that can explain this result are as follows: 1) all cases received endotamponades (silicone oil, gas, and air); and 2) two-step entry technique and aggressive suture placement was performed when required. Endophthalmitis did not develop in any case during follow-up. This study had several limitations: its retrospective and noncomparative nature, a small interventional case series without a control group, a short follow-up time without surgery time evaluation, and without videos and photos. It is the best way to compare cases by their severity and compare the tamponades in each. As the focal and broad fibrovascular membrane groups were small, we did not compare the anatomic and functional results of the groups. Moreover, it is a much more effective way to compare the efficacy and results of new equipments with those of old ones, as well as the effectiveness of different tamponades in similar cases.

Conclusion

In conclusion, segmentation and removal of fibrovascular membranes with 23 G TSV using high-speed vitrectomy (5,000 cpm) was observed to be safe and effective in the management of severe DFVP. Further randomized, prospective, and comparative studies, including a larger number of patients with a longer follow-up time, are required to come to a more reliable conclusion.
  65 in total

1.  Novel method to quantify traction in a vitrectomy procedure.

Authors:  Anderson Teixeira; Lawrence Chong; Naoki Matsuoka; Adrian Rowley; Jaw-Chyng Lue; Matthew McCormick; Ralph Kerns; Mark Humayun
Journal:  Br J Ophthalmol       Date:  2010-06-10       Impact factor: 4.638

Review 2.  Transconjunctival sutureless 23-gauge vitrectomy for diabetic retinopathy. Review.

Authors:  José G Arumí; Anna Boixadera; Vicente Martínez-Castillo; Borja Corcóstegui
Journal:  Curr Diabetes Rev       Date:  2009-02

3.  Clinical and histological features of epiretinal membrane after diabetic vitrectomy.

Authors:  Yung-Ray Hsu; Chung-May Yang; Po-Ting Yeh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-15       Impact factor: 3.117

4.  Intraoperative iatrogenic peripheral retinal break in 23-gauge transconjunctival sutureless vitrectomy versus 20-gauge conventional vitrectomy.

Authors:  Dong Min Cha; Se Joon Woo; Kyu Hyung Park; Hum Chung
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-16       Impact factor: 3.117

5.  Fifty consecutive cases of transconjunctival sutureless 23-gauge vitrectomy combined with phacoemulsification and IOL implantation.

Authors:  Werner W Hütz; Peter Hoffmann; Fritz Hengerer
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2011-09-15

6.  Comparative study between a standard 25-gauge vitrectomy system and a new ultrahigh-speed 25-gauge system with duty cycle control in the treatment of various vitreoretinal diseases.

Authors:  Stanislao Rizzo; Federica Genovesi-Ebert; Claudia Belting
Journal:  Retina       Date:  2011-11       Impact factor: 4.256

7.  Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.

Authors:  Hamid Ahmadieh; Nasser Shoeibi; Morteza Entezari; Ramin Monshizadeh
Journal:  Ophthalmology       Date:  2009-08-21       Impact factor: 12.079

8.  Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.

Authors:  Yusuke Oshima; Chiharu Shima; Taku Wakabayashi; Shunji Kusaka; Fumio Shiraga; Masahito Ohji; Yasuo Tano
Journal:  Ophthalmology       Date:  2009-03-09       Impact factor: 12.079

9.  Rate of sclerotomy suturing in 23-gauge primary vitrectomy.

Authors:  Renaud Duval; Joanna M Hui; Kourous A Rezaei
Journal:  Retina       Date:  2014-04       Impact factor: 4.256

10.  Comparison of retinal breaks observed during 23 gauge transconjunctival vitrectomy versus conventional 20 gauge surgery for proliferative diabetic retinopathy.

Authors:  Sharif A Issa; Alan Connor; Maged Habib; David Hw Steel
Journal:  Clin Ophthalmol       Date:  2011-01-20
View more
  1 in total

1.  Evaluation of Retinal Detachment After Diabetic Vitrectomy: Causes and Ways of Management.

Authors:  Ahmed M Abdelhadi; Hany Ahmed Helaly; Amr Abuelkeir
Journal:  Clin Ophthalmol       Date:  2020-01-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.